Oncology

Chimerix Acquires Oncoceutics to Expand Pipeline with Late-Stage Oncology Program

01/12/2021

Excerpt from the Press Release: DURHAM, NC, USA I January 8, 2021 I Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that the Company has acquired Oncoceutics, Inc., a privately-held, clinical-stage biotechnology company developing imipridones, a novel class of compounds. Oncoceutics’ lead…

Read More

Study points the way to boost immunotherapy against breast cancer, other solid tumors

01/04/2021

Excerpt from the Article: Boosting immune system T cells to effectively attack solid tumors, such as breast cancers, can be done by adding a small molecule to a treatment procedure called chimeric antigen receptor-T (CAR-T) cell therapy, according to a study by researchers at the UNC Lineberger Comprehensive Cancer Center. The boost helps recruit more…

Read More

Triple chemotherapy combination improves metastatic colorectal cancer outcomes

12/31/2020

Excerpt from the Press Release: Researchers from SWOG Cancer Research Network, a cancer clinical trials group funded by the National Cancer Institute (NCI), part of the National Institutes of Health, have shown that a triple drug combination – of irinotecan, cetuximab, and vemurafenib – is a more powerful tumor fighter and keeps people with metastatic…

Read More

Global trial reveals life saving drug for acute myeloid leukemia

12/30/2020

Excerpt from the Article: A landmark paper published today in the New England Journal of Medicine describes the results from a global trial across 148 sites in 23 countries, showing a 30 per cent improvement in survival in patients with acute myeloid leukemia (AML).  The Phase 3 clinical trial called QUAZAR, showed that a drug,…

Read More

PureTech Advances Wholly Owned Candidate LYT-200 into Phase 1 Trial for Potential Treatment of Metastatic Solid Tumors

12/18/2020

Excerpt from the Press Release: BOSTON–(BUSINESS WIRE)–PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced the initiation of its Phase 1 clinical trial of LYT-200 for the potential treatment of metastatic solid tumors that are…

Read More

Ambrx Presents Phase 1 Trial Data Update and Phase 2/3 Clinical Trial in Progress for Lead Program ARX788 at the 2020 San Antonio Breast Cancer Symposium

12/17/2020

Excerpt from the Press Release: SAN DIEGO, Dec. 10, 2020 /PRNewswire/ — Ambrx Inc., a clinical-stage biopharmaceutical company focused on developing Precision Biologics using an expanded genetic code, provided a clinical update on their lead program ARX788, a homogeneous and highly stable, site-specific antibody drug conjugate (ADC) targeting HER2 positive cancers. “As presented at the 2020…

Read More

A single number helps Stanford data scientists find most dangerous cancer cells

01/29/2020

“Biomedical data scientists at the Stanford University School of Medicine have shown that the number of genes a cell uses to make RNA is a reliable indicator of how developed the cell is, a finding that could make it easier to target cancer-causing genes.” Click the button below to read the entire Article! Continue Reading…

Read More

Google Shows AI Can Spot Breast Cancer Better Than Doctors

01/06/2020

According to new research from Google Health, AI can more accurately detect breast cancer than physicians. “The technology’s reading of mammograms reduced both false positives, where healthy patients are mistakenly diagnosed with the disease, and false negatives, where the cancer is missed, the Alphabet Inc. unit said in a blog post on Wednesday. The system reduced false positives by…

Read More